Tylenol maker’s stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a ‘major overreaction’
This week, Kenvue, the consumer health spin-off from Johnson & Johnson, found itself at the epicenter of a market tempest ...
